Law360, Los Angeles (February 28, 2014, 7:07 PM EST) -- Actelion Pharmaceuticals Ltd. reached a settlement with generic-drug makers in its quest for a New Jersey federal court to confirm antitrust laws don’t require the company to supply its patented blood pressure drug Tracleer for generics development, according to an order dismissing the case Friday.
U.S. District Judge Noel L. Hillman's dismissal leaves open the option for the parties to re-enter litigation if the deal isn’t consummated within 60 days. The settlement's terms were not disclosed.
When Actelion's suit was filed in September 2012, it heralded...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.